

AGC Inc.

Financial Results for FY2021 Second Quarter

August 2, 2021

Event Summary

[Company Name] AGC Inc.

[Company ID] 5201-QCODE

[Event Language] JPN

[Event Type] Earnings Announcement

[Event Name] Financial Results for FY2021 Second Quarter

[Fiscal Period] FY2021 Q2

[Date] August 2, 2021

[Number of Pages] 29

[Time] 16:30 – 17:33

(Total: 63 minutes, Presentation: 31 minutes, Q&A: 32 minutes)

[Venue] Webcast

[Venue Size]

[Participants]

[Number of Speakers] 4

Yoshinori Hirai Representative Director President, CEO Shinji Miyaji Representative Director, Senior Executive

Vice President, CFO, CCO, General Manager of Corporate Planning General Division

Toshiro Kasuya Senior Executive Officer, General Manager of

Finance & Control Division

Kazumi Tamaki General Manager of Corporate

Communications & Investor Relations

Division

Presentation

Tamaki: As the time has come, AGC Inc. will now begin its financial results briefing for the second quarter of the fiscal year ending December 2021.

This is Tamaki from the Corporate Communications & Investor Relations Office, and I will be your moderator today. Thank you.

First, I would like to introduce today's attendees. Yoshinori Hirai, Representative Director President, CEO. Shinji Miyaji, Representative Director, Senior Executive Vice President, CFO. Toshiro Kasuya, Executive Officer, General Manager of Finance & Control Division.

First, CFO Miyaji will provide an overview of the financial results for the second quarter of FY2021. After that, CEO Hirai will give a presentation on the progress of the mid-term management plan. Thereafter, we will move on to a question-and-answer session. The meeting is scheduled to close at 17:30, so please cooperate with us for the proceedings.

Mr. Miyaji, please.

Key points for today



■ Financial Results for 2Q FY2021 (YTD):

(vs. Apr 12 Forecast) (YoY)

Net Sales 811.3 bn JPY (+11.3 bn JPY) (+156.8 bn JPY)
Operating profit 95.2 bn JPY (+10.2 bn JPY) (+74.6 bn JPY)

- •Shipments and sales prices of architectural glass increased beyond the initial expectation.
- ·Sales prices of polyvinyl chloride (PVC) exceeded the forecast of April 12, 2021.
- Outlook for FY2021: (vs. Apr 12 Forecast) (YoY)

Net Sales 1,670.0 bn JPY (+20.0 bn JPY) (+257.7 bn JPY)
Operating profit 180.0 bn JPY (+20.0 bn JPY) (+104.2 bn JPY)

•The forecast has been upwardly revised as the PVC market will remain stronger than the initial expectation.

■ Shareholder return

- •Annual dividend was revised following the upward revision of the financial result forecast.
- •Special dividend has been added as a return for the temporary earnings from the transfer of the architectural glass business in North America.

©AGC Inc.

Miyaji: This is Miyaji, the CFO. I will now explain our business results for the second quarter.

First, please see page 4. This shows the key points for today.

Net sales for the first half of the fiscal year totaled JPY811.3 billion, with operating profit of JPY95.2 billion. Compared with the previous forecast, net sales and operating profit are upwardly revised by JPY11.3 billion and JPY10.2 billion, respectively, since shipments and sales prices of architectural glass and sales prices of polyvinyl chloride were higher than our expectation.

As for the forecast for the full year of 2021, we have again upwardly revised the previous forecast for net sales to JPY1.670 trillion, an increase of JPY20 billion from the previous forecast, and operating profit to JPY180 billion, an increase of JPY20 billion from the previous forecast, as the market for polyvinyl chloride is expected to remain at a higher level than expected.

The planned annual dividend will be revised upward in accordance with the upward revision of the earnings forecast for the current fiscal year. In addition, we expect to record a 1-time gain from the transfer of the architectural glass business in North America and plan to pay a special dividend at the end of the fiscal year.

Highlights of the Financial Results for 2Q. FY2021

* FOREX impact was +23.3 billion JPY, change in the scope of consolidation was +2.4 billion JPY



				(100 million JPY
	FY2020 1-2Q Total	FY2021 1-2Q Total	Change	Major factors in the change (+) Increasing factors (-)Decreasing factors
Net Sales	6,545	8,113	-1	 (+) Shipments of automotive and architectural glass increased (+) Shipments of life science and semiconductor products increased (+) Sales prices of PVC in Southeast Asia and architectural glass increased (+) Appreciation of Euro
Operating Profit	206	952	+ 746	In addition to the above, (+) Manufacturing costs decreased as the operating efficiency of glass manufacturing facilities improved (-) Depreciation expenses increased due to factors such as new facility launch for LCD glass substrate and semiconductor related products.
Profit before tax	165	971	+ 807	In addition to the above, (+) FOREX gain was posted.
Profit for the period Attributable to owners of the parent	114	638	+ 524	
FOREX (Average) JPY/USD JPY/EUR	108.27 119.30	107.70 129.83		
Crude Oil (Dubai, Average)	40.64	63.47		

@AGC Inc.

6

Please see page 6.

Sales were supported by increased shipments of automotive glass, architectural glass, Life Science products, and semiconductor-related products, as well as higher sales prices for polyvinyl chloride and architectural glass in Southeast Asia. In addition, the appreciation of the euro had an additional impact, resulting in a YoY sales increase of JPY156.8 billion.

Operating profit increased by JPY74.6 billion due to the previously mentioned factors of increased sales and reduced manufacturing costs associated with improved utilization of manufacturing facilities for architectural glass and automotive glass, despite an increase in depreciation costs associated with the start-up of new facilities for LCD glass substrates and semiconductor-related products.

Profit before tax exceeded operating profit by JPY97.1 billion, due to foreign exchange gains in other income, despite the recording of business structure improvement expenses related to the European glass business and loss on disposal of fixed assets as other expenses.

YoY Performance Comparison by Business Segment



					(100	million JPY)	
	FY2020		FY2	2021	Change		
	1-2Q	Total	1-2Q	Total	- Criai	.gc	
	(a)	(b)	(b)-	(a)	
	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	
Glass	2,942	▲ 208	3,717	203	+ 775	+ 411	
Electronics	1,386	174	1,415	140	+ 29	▲ 34	
Chemicals	2,124	227	2,881	595	+ 757	+ 368	
Ceramics/Other	382	14	367	16	▲ 15	+ 2	
Elimination	▲ 289	▲ 1	▲ 268	▲ 2	+ 21	▲ 1	
Total	6,545	206	8,113	952	+ 1,568	+ 746	

@AGC Inc.


7

Next, I would like to explain the business results by segment. Please refer to page 7.

Sales and profit increased in Glass and Chemicals, while sales and profit decreased in Electronics.

Variance Analysis on OP (1-2Q.FY2021 vs. 1-2Q.FY2020)





@ACC Inc

Please see page 8.

The following is an explanation of the factors that caused the difference in operating profit for the 6 months of FY2021 compared to the same period of the previous year.

Operating profit for the first half of FY2021 increased by JPY74.6 billion YoY to JPY95.2 billion.

The volume composition difference is a positive JPY23.6 billion. Shipments of Life Science products, automotive glass, architectural glass, and semiconductor-related products increased.

The difference in sales price is a positive JPY38.1 billion. Sales prices of polyvinyl chloride in Southeast Asia, architectural glass, and polyvinyl chloride monomer in Japan increased.

The price difference of raw materials and fuels is JPY3.4 billion. Despite the rise in European natural gas prices, valuation gains on oil hedges improved.

Difference of cost and others is positive JPY9.5 billion. Depreciation in the Electronics segment increased, but this was more than offset by the effect of improvements in the operating rates of manufacturing facilities for architectural glass and automotive glass.

Consolidated Statement of Financial Position



	2020/12	2021/6	Change	
Cash and cash equivalents	2,361	2,481	+ 119	
Inventories	2,748	3,003	+ 254	
Property, plant and equipment, Goodwill and Intangible assets	14,376	14,967	+ 590	
Other assets	5,859	6,359	+ 500	Faraign ayahanga
Total assets	25,345	26,809	+ 1,464 ←	Foreign exchange fluctuation +84.7 billion yen
Interest-bearing debt	7,880	7,565	▲ 314	+64.7 billion yen
Other liabilities	5,035	5,429	+ 395	
Liabilities	12,914	12,995	+ 80	
Total equity attributable to owners of the parent	11,151	12,381	+ 1,229	
Non-controlling interests	1,279	1,434	+ 155	
Equity	12,430	13,815	+ 1,384	
Total liabilities and equity	25,345	26,809	+ 1,464	
D/E ratio	0.63	0.55		

@AGC Inc.

9

Please see page 9.

Next, I will explain the balance sheet in comparison with the end of December 2020.

Total assets amounted to JPY2.6809 trillion, an increase of JPY146.4 billion from the end of December 2020. Of this amount, JPY84.7 billion was due to foreign exchange fluctuation.

The D/E ratio was 0.55, an improvement from the end of December 2020.

Consolidated Statement of Cash Flow



(100 million JPY) 1-2Q Total FY2020 FY2021 Profit before tax 165 971 Depreciation and amortization 722 796 Increase(decrease) in working capital 37 **▲ 175** Others 191 97 Cash flows from operating activities 1,115 1,690 Cash flows from investing activities ▲ 1,044 **▲ 925** Free cash flow 70 765 Changes in interest-bearing debt 2,801 **▲** 515 Dividends paid **▲** 133 **▲** 133 Others **A** 6 **▲** 53 Cash folws from financing activities 2,663 **▲** 701 Effect of exchange rate changes on **45** 56 cash and cash equivalents Net increase(decrease) in cash and 2,688 119 cash equivalents

©AGC Inc.

10

Please see page 10.

The following is an explanation of the statement of cash flows for the first half of 2021.

Operating cash flow was JPY169 billion, a significant YoY improvement, and investment cash flow was JPY92.5 billion, resulting in a positive free cash flow of JPY76.5 billion.

Against the backdrop of improved business performance, free cash flow improved by JPY69.5 billion YoY.

CAPEX, Depreciation and R&D



	(1	00 million JPY)	
	1-2Q	Total	Major projects for CAPEX
	(5)		·G11 investment in China (Electronics)
CAPEX	FY2020 1,116	FY2021 1,033 ←	Production facility enhancement for semiconductor-related products (Electronics)
Glass	282	251	·Capacity enhancement for fluorochemicals (Chemicals)
Electronics	364	342	·Capacity enhancement for PVC in Southeast
Chemicals	465	431	Asia (Chemicals)
Ceramics/Other	6	12	·Capacity enhancement for bio- pharmaceuticals (Chemicals)
Elimination	A 0	A 3	pharmaceuteais (chemicais)
Depreciation	722	796 ←	Major factors for increase
Glass	260	270	in depreciation cost
Electronics	238	280	 Production facility enhancement for semiconductor-related products (Electronics)
Chemicals	214	236	•G11 investment in China (Electronics)
Ceramics/Other	10	10	
Elimination	A 0	A 0	
R&D	219	238	

@AGC Inc.

11

Please see page 11.


This section explains capital expenditures, depreciation, and R&D expenses. Capital expenditures for the first half of 2021 totaled JPY103.3 billion.

In Electronics, investment in G11 for LCD glass substrates and enhancement of photomask blanks for EUV exposure. In Chemicals, we are increasing our capacity for PVC and biopharmaceuticals in Southeast Asia. Depreciation expenses increased by JPY7.4 billion YoY to JPY79.6 billion, and R&D expenses were JPY23.8 billion.

Glass Segment








(Architectural glass)

- Shipments, mainly in Europe and Indonesia, increased significantly.
- Sales prices increased in Europe and South America.
- Manufacturing costs declined as the operating efficiency of the manufacturing facilities improved mainly in Europe.

(Automotive glass)

- Though affected by semiconductor shortage, shipments increased as vehicle production increased in all regions.
- Manufacturing costs declined as the operating efficiency of the manufacturing facilities improved mainly in Japan/Asia and Europe.



@AGC Inc.

Next, please refer to page 13 for an explanation by segment.

In Glass, net sales for the first half of 2021 were JPY371.7 billion and operating profit was JPY20.3 billion, a YoY increase of JPY77.5 billion in net sales and a YoY increase of JPY41.1 billion in operating profit.

Architectural glass sales increased by JPY37.6 billion YoY to JPY188.3 billion, due to a significant increase in shipments, mainly to Europe and Indonesia, and higher sales prices, mainly in Europe and South America.

Automotive glass sales increased by JPY39.9 billion YoY to JPY182.2 billion, due to an increase in automotive production in all regions and an increase in our shipments, despite the impact of semiconductor shortages.

Operating profit increased by JPY41.1 billion YoY to JPY20.3 billion, due to the factors mentioned just now, including the increase in sales and the reduction in manufacturing costs resulting from the improvement in the operating rate of glass manufacturing facilities. Regarding the composition of operating profit in the Glass segment, architectural glass accounts for approximately 80%, and automotive glass accounts for approximately 20%.

FOREX impact: +14.5 billion yen, Change in the Scope of Consolidation: +40 million yen


Electronics Segment





(Display)

- •Shipments of LCD glass substrates remained at the same level YoY, while those of specialty glass for display applications increased.
- •Depreciation expenses increased because of the new facility launch for LCD glass substrate.
- Manufacturing costs increased as affected by foreign exchange fluctuation (Electronic materials)
 - ·Shipments of optoelectronic materials remained at the same level YoY.
 - •Shipments of semiconductor-related products such as EUV mask blanks and increased
 - Shipments of circuit board material decreased due to US-China trade friction and other factors.
 - Depreciation expenses increased because of the new facility launch for semiconductor-related products.



@AGC Inc.

14

Please see page 14.

In the Electronics segment, net sales were JPY141.5 billion and operating profit was JPY14 billion for the first half of 2021, a YoY increase of JPY2.9 billion in net sales and a YoY decrease of JPY3.4 billion in operating profit.

In display, although shipments of LCD glass substrates were at the same level as the same period of the previous year, shipments of specialty glass for displays increased, resulting in a YoY increase of JPY2.3 billion in sales. The shipment volume of LCD glass substrates decreased by a mid-digit percentage compared to the previous quarter. Due to tight business conditions, selling prices increased by a low single-digit percent YoY, and were on par with the same period last year.

In electronic materials, although shipments of printed circuit board materials decreased due to the impact of trade friction between the US and China, shipments of opto-electronics materials were on a par with the same period of the previous fiscal year, and shipments of semiconductor-related products, such as photomask blanks for EUV lithography, increased. As a result, overall sales of electronic materials increased by JPY200 million YoY.

Despite the factors contributing to the increase in sales just mentioned, operating profit was JPY14 billion, a YoY decrease of JPY3.4 billion, due to an increase in depreciation expenses associated with the start-up of new facilities for LCD glass substrates and semiconductor-related products, as well as the impact of foreign exchange rates.

In the Electronics segment, the ratio of operating profit to net sales is disclosed on a yearly basis because of the large fluctuation in quarterly performance due to the seasonal nature of customers.


Chemicals Segment



595

- 32

			(100 million JPY)
1	1-2Q T	Γotal	
	FY2020	FY2021	Change
Net sales	2,124	2,881	+ 757*
Chlor-alkali & Urethane	1,254	1,762	+ 508
Fluorochemicals & Specialty	529	568	+ 39
Life science	333	545	+ 212
(Inter-segment)	8	7	
Operating profit	227	595	+ 368
Operating profit	227	595	+ 36



(Chlor-alkali/urethane)


·PVC selling price increased in Southeast Asia.

(Fluorine/specialty chemicals)

- •Shipments of fluorochemical-related products continued recovering for automotive applications.
- Shipments of fluorochemical-related products for aircraft applications were sluggish.

(Life science)

- •The number of contracts increased for synthetic pharmaceuticals and agrochemicals.
- •The number of contracts for bio-pharmaceuticals increased for those relating to anti-coronavirus application, in addition to capacity enhancement through M&A and CAPEX.



Variance Analysis on OP

+269

@AGC Inc.

15

Please see page 15.

In the Chemicals segment, for the first half of 2021, net sales were JPY288.1 billion and operating profit was JPY59.5 billion, a YoY increase of JPY57.7 billion in net sales and a YoY increase of JPY36.8 billion in operating income.

Sales of chlor-alkali and urethane increased due to higher sales prices of PVC in Southeast Asia.

Fluorine and specialty chemicals reported an increase in sales, as shipments of fluorine-related products for the automotive industry are on a recovery trend, although shipments of fluorine-related products for the aircraft industry have been sluggish.

In Life Science, the number of orders received for synthetic pharmaceuticals and agrochemicals increased, and the number of orders received for biopharmaceuticals increased due to capacity expansion through acquisitions and capital investment. Moreover, the number of orders received for patients with the new coronavirus also increased.

Operating profit increased by JPY36.8 billion YoY to JPY59.5 billion, due to strong performances in chlor-alkali and urethane and Life Science, despite the impact of higher unit prices for inventory dispatch in fluorine and specialty chemicals due to lower capacity utilization.

As for the composition of operating profit in the Chemicals segment, chlor-alkali and urethane accounted for 70%, fluorine and specialty chemicals accounted for 10%, and Life Science accounted for about 20%.

Profit contribution of Strategic Business



Steady performance shown mainly in Life science



©AGC Inc.

16

Please see page 16.

I will now explain the results of our Strategic businesses.

Overall, the Strategic businesses posted sales of JPY112.1 billion and operating profit of JPY19.6 billion in the second quarter of 2021, a YoY increase of JPY22.7 billion in sales and a YoY increase of JPY1.9 billion in operating profit.

In the Electronics business, shipments of printed circuit board materials business were affected by the US-China trade friction and other factors, but increased shipments of semiconductor-related products, such as photomask blanks for EUV lithography, led to an increase in sales. In addition, the Life Science business is expanding steadily.

YoY Performance Comparison by Geographic Segment



	1-2Q T	1-2Q Total		
	FY2020	FY2021	Change	
Net sales	6,545	8,113	+ 1,568 •	FOREX impact: +23.3 billion JPY
Japan &Asia	4,431	5,257	+ 827	100 N 10 NN
Americas	682	895	+ 214	Change in the Scope of Consolidation:
Europe	1,433	1,961	+ 528	+2.4 billion JPY
Operating profit	206	952	+ 746	
Japan & Asia	419	837	+ 418	
Americas	▲ 17	72	+ 88	
Europe	▲ 24	231	+ 256	
Cross-regional common expenses	▲ 172	▲ 187	▲ 16	

@AGC Inc.

17

Please see page 17.

I would like to explain the business results by region for the first half of 2021 in comparison with the same period of the previous year.

In Japan and Asia, sales and profits increased due to higher selling prices of PVC in Southeast Asia and increased shipments of semiconductor-related products such as automotive glass and photomask blanks for EUV lithography.

In the United States, sales and profits increased due to higher selling prices and shipment volumes of architectural glass, as well as an increase in the number of contracts for biopharmaceutical products.

In Europe, sales and profit increased due to higher selling prices and shipment volumes for architectural glass, as well as an increase in the number of contracts for synthetic pharmaceuticals and biopharmaceuticals.

FY2021 Outlook



 Significant increase is expected in net sales and profit thanks to recovery of businesses affected by the coronavirus pandemic & continued high PVC prices.

_		(100 million JPY)
FY2020	FY2021e As of Apr 12, 2021	FY2021e As of Aug 2, 2021
14,123	16,500	16,700
758	1,600	1,800
571	1,420	1,870
327	830	1,170
120	140	210
		(Ordinary 160)
		(Special 50)
5.4%	9.7%	10.8%
2.9%	7.4%	10.5%*
SD 106.8	109.0	108.6
UR 121.8	129.4	129.5
3BL 42.2	63.8	69.2
/IT 713	1,000	1,012
	14,123 758 571 327 nt 120 5.4% 2.9% 9SD 106.8 UR 121.8 BBL 42.2	14,123 16,500 758 1,600 571 1,420 327 830 120 140 5.4% 9.7% 2.9% 7.4% 1SD 106.8 109.0 UR 121.8 129.4 BBL 42.2 63.8

^{*} ROE of FY2021e is calculated using the figures of Profit for the year attributable to owners of the parent as of Dec 31, 2020

@AGC Inc.

19

Please see page 19.

I would like to explain our business outlook for the full year of 2021.

As a result of the fact that low business performance due to the coronavirus crisis is on recovery trend and that the price of PVC continues to be high, the forecast for net sales has been revised upward from the previous forecast announced on April 12. As a result, net sales are expected to increase by JPY257.7 billion to JPY1.670 trillion and operating profit by JPY104.2 billion to JPY180 billion.

Profit before tax is expected to increase by JPY129.9 billion YoY to JPY187 billion, and net profit attributable to owners of the parent is expected to increase by JPY84.3 billion YoY to JPY117 billion.

We plan to pay a dividend of JPY210 per share, consisting of a regular dividend of JPY160 and a special dividend of JPY50.

We have revised our exchange rate assumptions for the full year to JPY108.6 for the US dollar and JPY129.5 for euro. We have also revised our full-year Dubai crude oil forecast to USD69.2 per barrel.

Shareholder Return



- Dividends increased following the upward revision of the forecast.
- Special dividend scheduled as a return for the temporary earnings from the transfer of the architectural glass business in North America.

Shareholder Return Policy

AGC will maintain stable dividends with a consolidated dividend payout ratio aiming for 40% while comprehensively examining the consolidated business performance and capital demand, etc. We will implement flexible share buybacks as a shareholder return measure worth improved capital efficiency.

	(yen)	Interim	Year-end	Special	Year-total	Consolidated payout ratio
FY2	2020	60	60	-	120	81%
	Initial (Feb)	60	60	-	120	-
EV20210	Apr 12	70	70	-	140	
FY2021e	Aug 2	80 (Actual)	80	50	210	40%

^{*2015-2017} dividends per share were calculated with consideration to the share consolidation held in July 2017.

@AGC Inc.

20

Please see page 20.

I would like to explain about shareholder return.

The annual dividend for FY2021 has been revised upward in line with the further upward revision of the earnings forecast for the current fiscal year as in April. In FY2021, we plan to pay a special dividend of JPY50 per share at the end of the fiscal year, as the net profit attributable to owners of the parent company is expected to include a 1-time gain from the transfer of the architectural glass business in North America.

Outlook of Net sales/Operating profit by segment



		119					421		(100	million JPY)
	FY2	2020	FY2	2021	FY20	21e	FY2	2021	Char	nge
	full-	year	1-2Q	total	3-4Q	total	full-year	forecast	(b)-	St (1976)
	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit
Glass	6,510	▲ 166	3,717	203	3,683	147	7,400	350	▲ 35	▲ 56
Electronics	2,894	378	1,415	140	1,785	190	3,200	330	+ 370	+ 50
Chemicals	4,512	505	2,881	595	2,919	505	5,800	1,100	+ 37	▲ 90
Ceramics/Other	811	42	367	16	433	4	800	20	+ 65	▲ 12
Elimination	▲ 603	1	▲ 268	A 2	▲ 232	2	▲ 500	0	+ 36	+ 4
Total	14,123	758	8,113	952	8,587	848	16,700	1,800	+ 473	▲ 104

©AGC Inc. 2

Please see page 21.

This is our business forecast by segment.

Compared with the results for the first half of the fiscal year, sales and profits of Glass are expected to decrease, those of Electronics are expected to increase, and those of Chemicals are expected to decrease.

2H Outlook by Business Segment



		2021 1H vs 2021 2H								
	Glass	(Architectural glass) •Net sales will drop due to a seasonal shipment decrease in Europe and the transfer of the business in North America. (Automotive glass) •Global vehicle production might be affected by semiconductor shortage.								
E	lectro nics	(Display) - Shipments of LCD glass substrates will remain strong in 2H Specialty glass for display applications will remain strong in 2H following the recovery of the smartphone market Depreciation expense will increase due to the launch of new facility for LCD glass substrates. (Electronic materials) - Shipments of semiconductor related materials and optoelectronics materials will increase in 2H Depreciation expense will increase due to the launch of new facility for semiconductor-related products.								
C	Chemi cals	(Chlor-alkali/urethane) •Though softening, the PVC market will remain high. (Fluorine/specialty chemicals) •Demand for automotive applications will pick up gradually while shipments for aircraft applications remains sluggish. (Life science) •Business will remain strong by capturing demand with capacity enhancement through M&A and CAPEX, also due to contracts relating to anti-coronavirus vaccines.								

@AGC Inc.

22

Please see page 22.

The following is an explanation of the outlook for the second half of 2021 compared to the first half for each business.

In the Glass segment, architectural glass sales are expected to decline due to lower shipments in Europe, as a result of seasonality, as well as the impact of the transfer of the North American business. For automotive glass, there is concern that global vehicle production will continue to be impacted by the semiconductor shortage after the second quarter.

In the Electronics segment, among displays, shipments of LCD glass substrates are expected to remain firm in the second half of the fiscal year. Prices are expected to remain the same in the third quarter and beyond as they were in the second quarter, when they rose to reflect tight supply and demand. Shipments of specialty glass for displays are expected to remain strong in the second half of the fiscal year as the smartphone market recovers. In electronic materials, shipments of semiconductor-related products and optoelectronics components are expected to increase in the second half.

On the other hand, depreciation expenses are expected to increase due to the start-up of new facilities for LCD glass substrates and semiconductor-related products.

In the Chemicals segment, chlor-alkali and urethanes remained at high levels, although soaring market prices for PVC eased. Demand for caustic soda is expected to recover gradually. In fluorine and specialty products, shipments of products for aircraft will continue to be weak, but demand for automotive applications is expected to recover gradually.

The Life Science business is expected to grow steadily, thanks to further demand initiatives through capacity expansion by acquisitions and capital investments, as well as contracts related to the development of new coronavirus vaccines.

Accelerating the Growth of Strategic Businesses



- No change from the announcement in May 2021
- Expected to make a steady growth



*Sales outlook of Strategic Business for FY2021 were revised upward at the time of the announcement for FY2021.1Q result.

@AGC Inc.

23

Please see page 23.

The outlook for the strategic businesses remains unchanged from that announced in May of this year. We expect our business performance to expand steadily.

CAPEX, Depreciation and R&D



(100 million JPY)

Full year

	FY2020	FY2021e	
CAPEX	2,413	2,200*←	Major projects for CAPEX •G11 investment in China (Electronics)
Glass	641	480	·Production facility enhancement for
Electronics	807	730	semiconductor-related products (Electronics) •Acquire a Gene therapy medicine plant
Chemicals	952	970	(Chemicals) • Capacity enhancement for fluorochemicals
Ceramics/Other	15	20	(Chemicals)
Elimination	A 2	0	• Capacity enhancement for PVC in Southeast Asia (Chemicals)
Depreciation	1,437	1,600	•Capacity enhancement for bio- pharmaceuticals (Chemicals)
Glass	510	500	priarriaceateas (criefficals)
Electronics	479	600	
Chemicals	430	480	
Ceramics/Other	19	20	
Elimination	▲ 1	0	
R&D	464	550	

^{*} Changed from the initial forecast of 200 billion yen (Initially, the Electronics Segment was 68 billion yen and the Chemicals Segment was 82 billion yen).

@AGC Inc.

24

Please see page 24.

We have revised upward our annual capital expenditure forecast from JPY200 billion at the beginning of the fiscal year to JPY220 billion, due to increased investment in the acquisition of assets in the Life Science business. The forecast for depreciation of JPY160 billion and research and R&D expenses of JPY55 billion remain unchanged from those announced at the beginning of the fiscal year.

That's all from me. Thank you.

Tamaki: Thank you very much, Mr. Miyaji. Mr. Hirai, please continue.

Strategies under AGC plus-2023



■ AGC will accelerate the following strategies toward Vision 2030.

Pursuing ambidextrous management

- •We will accelerate the growth in the strategic business area, and at the same time explore new business areas including those related to energy.
- •In the core business, we will conduct a structural reform in the architectural glass and automotive glass businesses that need improvements in profitability and asset efficiency.
- •For other businesses in the core business area, we will strengthen their profit foundation and cash generation.

Promotion of sustainability management

- Propelling materials innovation to help solve social issues
- ·Aiming for net-zero carbon in 2050
- Strengthening human resources and group-wide governance



Gaining competitiveness by accelerating digital transformation

- •Taking a transformation of the business model itself into consideration, leverage digital technologies to improve the process from product development to sales activities
- Use digital technologies to provide value to customers and society and gain competitiveness

©AGC Inc.

26

Hirai: This is Hirai, the CEO. I would like to explain the progress of our medium-term management plan, AGC plus-2023.

In February of this year, we announced our long-term vision, "Where we want to be in 2030." In order to ensure the realization of this plan, we have announced AGC plus-2023 as our new medium-term management plan.

The new medium-term management plan consists of 3 pillars.

The first is the pursuit of ambidextrous management, with the core business and the strategic businesses as the 2 wheels. We will continue to aim for an optimal business portfolio.


The second point is the promotion of sustainability management. By doing so, AGC has declared its commitment to contribute to the resolution of social issues and to achieve a carbon net zero by 2050.

The third is to strengthen our competitiveness by accelerating DX.

AGC plus-2023 Financial Targets



■ Expect to achieve the OP, ROE and D/E target at the first year



@AGC Inc.

27

These are the financial targets for 2023 of AGC plus-2023, which was announced at the same time.

As explained earlier, by significantly exceeding our initial plan, we expect to achieve our targets for operating profit, ROE, and D/E ratio this year. In addition, operating profit from the strategic businesses is growing faster than initially planned.

Performance Trend: Operating profit



■ Expected to achieve the third highest OP in FY2021

Operating Profit by Business Segment (100 million JPY) 2,292 1,975 1,657 1,540 1,366 867 1,182 1,196 1,206 1,016 758 1,018 963 799 712 621 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Electronics Chemicals Chemicals/Other Glass

*JGAPP in 2005 - 2011, and IFRS in 2012 - 2021e

@AGC Inc.

28

As for operating profit, the chart shows operating profit for the past 10 or more years.

We are forecasting the third highest operating profit in our history, but the content of this forecast has changed significantly.

11 years ago, in 2010, AGC achieved its highest profit. However, at that time, most of the profit was generated from the Electronics field, especially from glass substrates for flat panel displays, but this year's profit will be generated from each of the 3 business fields.


In this chart, Chemicals seem to occupy a very large portion, but you can see that, even within Chemicals, the structure is changing to generate profits from multiple business groups, such as the Chlor-Alkali business, the Fluorine and Specialty Chemicals business, and the Life Science business.

Performance Trend: Profit for the period attributable to owners of the parent



■ Expected to achieve the second highest profit for the period attributable to owners of the parent

Profit for the period attributable to owners of the parent (100 million JPY)



*JGAPP in 2005 - 2011, and IFRS in 2012 - 2021e

@AGC Inc.


29

Profit for the period is expected to be the second highest in our history.

Shareholder Return



■ Expected to achieve the record high in the year-total dividend per share




As Mr. Miyaji explained earlier, the annual dividend is also expected to reach a record high, with a regular dividend of JPY160 and a special dividend of JPY50.

Accelerating the Growth of Strategic Businesses



■ Centering on Life science, strategic businesses are expanding at the speed beyond the initial expectation.



*Sales outlook of Strategic Business for FY2021 were revised upward at the time of the announcement for the FY2021.1Q result. ©AGC Inc.

Now, I would like to talk about our Strategic businesses, which are also the drivers of our current growth.


When we announced our vision for 2025 in 2016, we defined existing businesses as our core businesses, and new growth areas with high profit potential as our Strategic businesses. Our Strategic businesses are in the areas of Electronics, Life Science, and Mobility.

Since then, we have been growing steadily, and last year, we were not affected by the coronavirus crisis and grew steadily. We expect to achieve sales of JPY250 billion and operating profit of JPY55 billion this year.

Life science Performance Trend



■ Steady growth and increase of OP margin



In this section, I would like to explain in more detail about Life Science, which is a major growth driver, along with Electronics.


In 2016, when we set it as a Strategic business, the Life Science business was still a very small business. That year, the following year, 2017, we entered a major growth trajectory with the acquisition of Bio-CDMO businesses in Europe and the United States.

Since then, we have achieved sales growth of over 30% per year, as you can see here. On the other hand, the operating profit margin is also improving as the production scale expands and currently stands at around 20%.

Top position: SUB in Bio-pharmaceutical CDMO



- Top-position* in rare diseases and orphan drugs by leveraging the competitiveness in SUB**
- Business grows based on active capacity expansion.



*Excluding China **SUB : Single-use bag bioreactor

**Other companies' capacity: AGC's estimate based on published information

@AGC Inc.

33

One of the features of our biopharmaceutical CDMO is the single-use back, which is a small 2,000-liter culture tank. Taking advantage of the characteristics of having multiple of these, we have established a top position in the field of rare diseases and orphan drugs.


In this figure, the bar graph shows sales, and the line graph shows the capacity of single-use bag.

The first step in the Life Science CDMO business is to secure production capacity. After that, we expand our orders and production goes up. This is also the reason why the operating profit margin is getting higher, as I mentioned earlier. As we have already planned, we will continue to increase the capacity of single-use bags and expand our sales.

Active Investment Expands the Foundation of Life science Business



■ Approx. 200bn JPY* investments have been made to expand the business foundation from synthetic pharmaceuticals & agrochemicals to bio-pharmaceuticals and gene/cell therapy CDMO.



AGC will continue capacity enhancement (including M&A) for further business expansion.

*Total investment in 2016 -2021e

*Average market growth: AGC's calculation based on available materials

@AGC Inc.

34

To date, the AGC Group has invested approximately JPY200 billion. This includes both M&A and capital expenditures.

We have secured technologies and production systems in these 3 areas: synthetic pharmaceuticals and agrochemicals using chemical synthesis, which have been the mainstay of conventional medicine; biopharmaceuticals using microorganisms and animal cells; and cutting-edge gene and cell therapy CDMO.

In the area of biopharmaceuticals, we have been engaged in CDMO of biopharmaceuticals using microorganisms in Japan for a long time, but our entry into the US and Europe started with M&A in 2016 to 2017. Later in 2019, the company acquired a plant for contract manufacturing of synthetic pharmaceuticals in Spain. And last year, we acquired a CDMO, a gene cell therapy company in Italy.

Since then, we have increased our manufacturing capacity through both our own capital investment and the acquisition of plants from pharmaceutical manufacturers. In the future, the AGC Group plans to continue to increase its capacity for further business expansion.

Aim at 200 bn JPY Net Sales from Life science Business in 2025



■ By leveraging the strength of the AGC Group and active business expansion, AGC sets the sales target in 2025 to 200 billion JPY, up from 180 billion JPY.

AGC Group's Strength



©AGC Inc.

25

Our strengths are our technical capabilities, such as single-use technologies and the ability to develop various generation and synthesis processes, our experience in manufacturing commercial pharmaceuticals, our ability to comply with FDA and other regulatory inspections, and our ability to provide high-quality CDMO services in Europe, the US, and Japan. We have a production system that meets the needs of our customers.

By leveraging these strengths and aggressively expanding our business base, we would like to raise our sales target for 2025 from JPY180 billion to JPY200 billion.

We hope to continue to grow AGC's Life Science business through proactive approaches.

That is all.

Tamaki: Thank you very much.

[END]